Report Categories
View AllRecent Articles
View All
PCSA Processa Pharmaceuticals posts worsethanexpected Q4 2025 EPS results that miss estimates by 68 percent as shares edge 033 percent lower
HYLN Hyliion Holdings reports slight Q4 2025 EPS miss shares rise 159 percent on positive investor sentiment
OYSEU Oyster management details strategic acquisition search priorities as it evaluates highpotential private market targets